16. クロウ・深瀬症候群
［臨床試験数：12，薬物数：18（DrugBank：8），標的遺伝子数：5，標的パスウェイ数：79］
Searched query = "Crow-Fukase syndrome", "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04396496 (ClinicalTrials.gov) | September 22, 2020 | 15/5/2020 | Treatment of POEMS Syndrome With Daratumumab | A Phase II Trial for the Treatment of POEMS Syndrome With Daratumumab | POEMS Syndrome | Drug: Daratumumab Injection | University of Arkansas | Janssen Scientific Affairs, LLC | Recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States |